Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023
Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024
Related news for (AGRX)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, TBNK, AGRX, UMBF on Behalf of Shareholders
- AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction – Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024